Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss-Reference-Cited by-同舟云学术

Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss

Published:2014-11 Issue: Volume:90 Page:71-81
ISSN:0039-128X
Container-title:Steroids
language:en
Short-container-title:Steroids

Author:

Komm Barry S.,Mirkin Sebastian,Jenkins Simon N.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Pharmacology,Endocrinology,Molecular Biology,Biochemistry

Reference90 articles.

1. Duavee [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, A subsidiary of Pfizer Inc.; 2013.

2. The 2012 hormone therapy position statement of: The North American Menopause Society;Menopause,2012

3. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group;Woodruff;Am J Obstet Gynecol,1994

4. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding;Lethaby;Cochrane Database Syst Rev,2004

5. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials;Manson;JAMA,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper;International Journal of Gynecology & Obstetrics;2024-01-04

2. Research advances in drug therapy of endometriosis;Frontiers in Pharmacology;2023-06-21

3. Menopause Is a Natural Condition: Does It Require to Be Corrected? For Whom and for How Long?;Amenorrhea;2023

4. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer;Trials;2022-12-05

5. Epigenetic and transcriptome responsiveness to ER modulation by tissue selective estrogen complexes in breast epithelial and breast cancer cells;PLOS ONE;2022-07-21